<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Adv Biomed Res</journal-id><journal-id journal-id-type="iso-abbrev">Adv Biomed Res</journal-id><journal-id journal-id-type="publisher-id">ABR</journal-id><journal-title-group><journal-title>Advanced Biomedical Research</journal-title></journal-title-group><issn pub-type="ppub">2277-9175</issn><issn pub-type="epub">2277-9175</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25590023</article-id><article-id pub-id-type="pmc">4283253</article-id><article-id pub-id-type="publisher-id">ABR-3-245</article-id><article-id pub-id-type="doi">10.4103/2277-9175.146365</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Comparison between antibiotic therapy of <italic>Brucellosis</italic> with and without vitamin A</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Salehi</surname><given-names>Marziyeh</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Salehi</surname><given-names>Hassan</given-names></name><xref ref-type="aff" rid="aff2">1</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Salehi</surname><given-names>Mohamad Mahdi</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib><contrib contrib-type="author"><name><surname>Salehi</surname><given-names>Maryam</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib></contrib-group><aff id="aff1">Student Research Center, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff2"><label>1</label>Department of Infectious Disease, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff3"><label>2</label>Student Research Center, Faculty of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Hassan Salehi, Department of Infectious Diseases, Isfahan University of Medical Sciences, Isfahan, Iran. E-mail: <email xlink:href="h_salehi@med.mui.ac.ir">h_salehi@med.mui.ac.ir</email></corresp></author-notes><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>06</day><month>12</month><year>2014</year></pub-date><volume>3</volume><elocation-id>245</elocation-id><history><date date-type="received"><day>10</day><month>6</month><year>2012</year></date><date date-type="accepted"><day>11</day><month>2</month><year>2013</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2014 Salehi.</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><sec id="st1"><title>Background:</title><p>Brucellosis is one of the endemic diseases in our country and it can be in the types of acute, sub-acute or chronic. It estimates that about 20% of Brucellosis may change from acute to chronic. Because cell mediated immunity (CMI) is the main defense of body against <italic>Brucella</italic> species, it seems that some degree of Immunologic disorders existed in the patients with chronic form of diseases and some supplements such as Vitamin A (Vit A) as an immunomodulator can stimulate CMI and may decrease the rate of chronicity.</p></sec><sec id="st2"><title>Materials and Methods:</title><p>In a single-blind randomized clinical trial 120 patients with the clinical and serological diagnosed Brucellosis were randomized. A total of 60 patients received streptomycin and Doxycycline as standard therapy for 6 weeks and others in addition to this Regimen received Vit A for about 4 weeks.</p></sec><sec id="st3"><title>Results:</title><p>In the case group, only 1 case (1.6%) relapsed and in the control group 8 (13.5%) with significant difference (<italic>P</italic> &#x0003c; 0.005) between two groups. Morbidity of disease was different between two groups.</p></sec><sec id="st4"><title>Conclusion:</title><p>Vit A therapy in the patients with Brucellosis with may reduce the disease morbidity and rate of chronicity.</p></sec></abstract><kwd-group><kwd>Brucellosis</kwd><kwd>immunity</kwd><kwd>vitamin A</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Brucellosis is one of the endemic diseases in Iran, especially in our city Isfahan. Unpasteurized dairy products are the main causes of transmission to human also it is a zoonotic disease.</p><p>It is a disease of animal (Zoonosis) that under certain circumstances can be transmitted to humans.[<xref rid="ref1" ref-type="bibr">1</xref>]</p><p>Although it occurs world-wide, brucellosis is more common in countries that do not have effective animal health program.[<xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref3" ref-type="bibr">3</xref>]</p><p>As one of the first bacteria to be weaponized, <italic>Brucella</italic> remains a potential bioterrorism agent[<xref rid="ref4" ref-type="bibr">4</xref><xref rid="ref5" ref-type="bibr">5</xref>] and all confirmed cases should have epidemiologic evaluation.[<xref rid="ref6" ref-type="bibr">6</xref>]</p><p>Muscoloskeletal involvement is the main problem, morbidity, and debility frequently was seen in this disease.</p><p>Spink reports 20% chronicity in about 2,000 cases of brucellosis which it elongates greater than 1 year.[<xref rid="ref7" ref-type="bibr">7</xref>]</p><p>Because cell mediated immunity (CMI) is the main defensive mechanism of body in this disease,[<xref rid="ref8" ref-type="bibr">8</xref>] it's seems that immunodeficient and malnourished patient more susceptible to this form of disease.</p><p>In Kurmanova <italic>et al</italic>. study, a clinical trials, demonstrated that the use of Vitamin A (Vit A) in a dose of 33,000 IU thrice a day for 10-12 days during the complex treatment of patients with acute (36 persons) and sub-acute (57 persons) brucellosis lowered the average period of manifestation of the disease (clinical signs)[<xref rid="ref9" ref-type="bibr">9</xref>] because it formation of antibodies, the lymphocyte blast cell transformation, the total number and subpopulation of the active T-cells. In Dizer <italic>et al</italic>. study levamisole administration as a supplement concomitantly with conventional antibiotic therapy has no immunostimulating effect on the basis of the lymphocyte subgroups ratios and the ability of phagycytosis measured.[<xref rid="ref10" ref-type="bibr">10</xref>]</p><p>In Chandra study, showed that deficiency of, Fe, Zn, Vit B6, Vit A, Cu, Na and Vit D had long-term effect on CMI.[<xref rid="ref11" ref-type="bibr">11</xref>]</p><p>In a pilot study by Salehi, it was revealed that Vit A as a supplement therapy can reduce the late complications of bruceelosis such as relapse.[<xref rid="ref12" ref-type="bibr">12</xref>]</p><p>The main object of this study was comparison between the standard therapy of brucellosis with and without Vit A.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>MATERIALS AND METHODS</title><p>In a research project with the number of 75,005, which was approved by the Ethics Committee of Isfahan University of medical sciences, a semiexperimental and prospective clinical trial study was done on 120 cases of brucellosis. Inclusion criteria were: Documentation of positive serologic enzyme-linked immuno sorbent assay (ELISA) test and then confirmation by standard tube agglutination test (STA).</p><p>Exclusion criteria were patients &#x0003c; 8 years old, disorders of eye, ear and kidney and pregnant women.</p><p>By random selection, 60 patients received standard treatment of brucellosis streptomycin 15 mg/kg/d and Doxycylin 100 mg twice daly for about 6 weeks and 25,000 unit Vit A daily for about 4 weeks (case group), and 60 patient received only standard therapy of Brucellosis (control group) all the patients were unaware about the received drugs. Patients in both groups were clinically followed and examined continuously and by filling the questionnaires based on subjective symptoms such as fever, chills, sweating, anorexia, arthralgia, myalgia, anorexia, and objective signs such as fever and arthritis.</p><p>Duration of subjective symptoms and sings, chronicity and relapses in both group compared for about 1 year [<xref ref-type="fig" rid="F1">Figure 1</xref>].</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Patients who entered the study, where devided in two study groups, followed up and analysed</p></caption><graphic xlink:href="ABR-3-245-g001"/></fig><p>Results were analyzed by using the SPSS software version 20.</p></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><p>In both groups, 40 persons (66%) were men and 20 persons (34%) were women [<xref ref-type="table" rid="T1">Table 1</xref>].</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Brucellosis patient's by sex and location</p></caption><graphic xlink:href="ABR-3-245-g002"/></table-wrap><p>Almost all cases had consumed unpasteurized dairy products. 84 persons (70%) of all cases were from around of Isfahan (Rehnan, Khomeini shahr, Fereidan, Zarinshahr and shahreza) and 36 cases (30%) from Isfahan.</p><p>Almost all cases (about 85%) had musculoskeletal involvement such as sacroileitis (with low back pain), knee and hip arthritis. Furthermore, they had evening and night fever and sweating. Serology by Enzyme limulus assay test and confirmatory STA test were positive in all cases and its ranges were between <inline-graphic xlink:href="ABR-3-245-g003.jpg"/> and <inline-graphic xlink:href="ABR-3-245-g004.jpg"/>.</p><p>Comparison of signs and symptoms showed defervescence (4, 6 days), pain and restriction of range of motion in joints (10, 14 days), sweating (5, 6 days), Arthralgia and myalgia (12, 14 days) and Anorexia (2, 2 weeks) were in case and control groups respectively [<xref ref-type="table" rid="T2">Table 2</xref>].</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Brucellosis patient's by recovery of signs and symptoms</p></caption><graphic xlink:href="ABR-3-245-g005"/></table-wrap><p>In the case group, 1 case (1.6%) was changed to the chronic and 1 case (1.6%) relapsed, and in control group, 5 cases (8%) became chronic and 8 cases (13.5%) relapsed. The statistical analysis was carried out by one-way ANOVA, which showed significant differences between two groups (<italic>P</italic> &#x0003c; 0.005) [<xref ref-type="table" rid="T3">Table 3</xref>].</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Brucellosis patient's by chronicity and relapse</p></caption><graphic xlink:href="ABR-3-245-g006"/></table-wrap></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>Brucellosis is a Zoonotic disease and in this study, its incidence and prevalence in men is more than women, which is compatible with Corbel and Nicholas study.[<xref rid="ref13" ref-type="bibr">13</xref>]</p><p>Mosculoskeletal involvement was the most frequent complication up to 80% in Colmenero <italic>et al</italic>. study[<xref rid="ref14" ref-type="bibr">14</xref>] and in our study it was seen in 85% of cases and it is compatible with study that study. For treatment of Brucellosis the combination of doxycycline plus gentamycin provides excellent results.[<xref rid="ref15" ref-type="bibr">15</xref><xref rid="ref16" ref-type="bibr">16</xref>] In Lulu <italic>et al</italic>. study, two drug combinations of streptomycin and tetra cycline, streptomycin and rifampicin or streptomycin and doxycycline were effective, but one of five patients with the chronic brucellosis relapsed. A combination of streptomycin, tetracycline, and rifampicin with or without steroids was used successfully in complications of brucellosis.[<xref rid="ref17" ref-type="bibr">17</xref>]</p><p>In Kurmanova <italic>et al</italic>. clinical trial study demonstrated that the use of Vit A during the complex of patients with acute and sub-acute Brucellosis lowered the average period of manifestation of the disease clinical signs[<xref rid="ref9" ref-type="bibr">9</xref>] and also in our study mean duration of clinical signs and symptoms decreased [<xref ref-type="table" rid="T3">Table 3</xref>].</p><p>In my pilot study in 2000 Vit A as a supplementation therapy could influence on outcome of brucellosis and reducing the late complication of brucellosis such as relapse.[<xref rid="ref11" ref-type="bibr">11</xref>] This study is also compatible with the pilot study of Salehi.[<xref rid="ref12" ref-type="bibr">12</xref>]</p><p>Comparison of chronicity between case and the control group was 1.6% and 8% respectively with significant difference meaning (<italic>P</italic> = 0.005) and also relapses was 1.6% and 13.5% in case and control group respectively with significant difference meaning (<italic>P</italic> &#x0003c; 0.005). The limitation of this study was small sample size and further studies with more cases are needed.</p></sec><sec sec-type="conclusion" id="sec1-5"><title>CONCLUSION</title><p>Treatment of Brucellosis with antibiotics and Vit A as a supplement and immunomedulator can reduce the morbidity and chronicity of disease.</p></sec></body><back><ack><title>ACKNOWLEDGEMENT</title><p>Authors acknowledge the Vice chancellor in research, Isfahan University of Medical Sciences for approve of this study.</p></ack><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Vice chanceller of research. Isfahan University of Medical Sciences</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pappas</surname><given-names>G</given-names></name><name><surname>Akritidis</surname><given-names>N</given-names></name><name><surname>Bosilkovski</surname><given-names>M</given-names></name><name><surname>Tsianos</surname><given-names>E</given-names></name></person-group><article-title>Brucellosis</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><fpage>2325</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">15930423</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kozukeev</surname><given-names>TB</given-names></name><name><surname>Ajeilat</surname><given-names>S</given-names></name><name><surname>Maes</surname><given-names>E</given-names></name><name><surname>Favorov</surname><given-names>M</given-names></name></person-group><collab>Centers for Disease Control and Prevention (CDC)</collab><article-title>Risk factors for brucellosis &#x02013; Leylek and Kadamjay districts, Batken Oblast, Kyrgyzstan, January-November, 2003</article-title><source>MMWR Morb Mortal Wkly Rep</source><year>2006</year><volume>55</volume><fpage>31</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">16645580</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pappas</surname><given-names>G</given-names></name><name><surname>Papadimitriou</surname><given-names>P</given-names></name><name><surname>Akritidis</surname><given-names>N</given-names></name><name><surname>Christou</surname><given-names>L</given-names></name><name><surname>Tsianos</surname><given-names>EV</given-names></name></person-group><article-title>The new global map of human brucellosis</article-title><source>Lancet Infect Dis</source><year>2006</year><volume>6</volume><fpage>91</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16439329</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>MH</given-names></name><name><surname>Glynn</surname><given-names>MK</given-names></name><name><surname>Groseclose</surname><given-names>SL</given-names></name></person-group><article-title>Endemic, notifiable bioterrorism-related diseases, United States, 1992-1999</article-title><source>Emerg Infect Dis</source><year>2003</year><volume>9</volume><fpage>556</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">12737739</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yagupsky</surname><given-names>P</given-names></name><name><surname>Baron</surname><given-names>EJ</given-names></name></person-group><article-title>Laboratory exposures to <italic>brucellae</italic> and implications for bioterrorism</article-title><source>Emerg Infect Dis</source><year>2005</year><volume>11</volume><fpage>1180</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">16102304</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><collab>Centers for Disease Control and Prevention (CDC)</collab><article-title>Suspected brucellosis case prompts investigation of possible bioterrorism-related activity &#x02013; New Hampshire and Massachusetts, 1999</article-title><source>MMWR Morb Mortal Wkly Rep</source><year>2000</year><volume>49</volume><fpage>509</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">10882289</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spink</surname><given-names>WW</given-names></name><name><surname>Farreras</surname><given-names>P</given-names></name><name><surname>Pedro-Pons</surname><given-names>A</given-names></name></person-group><article-title>What is chronic brucellosis?</article-title><source>Ann Intern Med</source><year>1951</year><volume>35</volume><fpage>258</fpage><lpage>74</lpage></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yingst</surname><given-names>S</given-names></name><name><surname>Hoover</surname><given-names>DL</given-names></name></person-group><article-title>T cell immunity to brucellosis</article-title><source>Crit Rev Microbiol</source><year>2003</year><volume>29</volume><fpage>313</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">14636042</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurmanova</surname><given-names>KB</given-names></name><name><surname>Ishchanova</surname><given-names>RZh</given-names></name><name><surname>Sakhisheva</surname><given-names>SSh</given-names></name><name><surname>Studentsova</surname><given-names>VK</given-names></name><name><surname>Tsirel&#x02019;son</surname><given-names>LE</given-names></name><name><surname>Alshinbaeva</surname><given-names>GU</given-names></name></person-group><article-title>Increasing the effectiveness of antibiotic therapy by correcting immunologic disorders with vitamin A in patients with brucellosis</article-title><source>Antibiot Khimioter</source><year>1990</year><volume>35</volume><fpage>35</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">2126706</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dizer</surname><given-names>U</given-names></name><name><surname>Hayat</surname><given-names>L</given-names></name><name><surname>Beker</surname><given-names>CM</given-names></name><name><surname>G&#x000f6;renek</surname><given-names>L</given-names></name><name><surname>Ozg&#x000fc;ven</surname><given-names>V</given-names></name><name><surname>Pahsa</surname><given-names>A</given-names></name></person-group><article-title>The effect of the doxycycline-rifampicin and levamisole combination on lymphocyte subgroups and functions of phagocytic cells in patients with chronic brucellosis</article-title><source>Chemotherapy</source><year>2005</year><volume>51</volume><fpage>27</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">15722630</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandra</surname><given-names>PK</given-names></name></person-group><article-title>Nutritent and Immunoregulation</article-title><source>J Nutr</source><year>1992</year><volume>122</volume><issue>Suppl 3</issue><fpage>754</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">1542043</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salehi</surname><given-names>H</given-names></name></person-group><article-title>Comparing standard treatment of brucellosis with and without Vitaamin A</article-title><source>J Isfahan Med Sch (I.U.M.S)</source><year>2003</year><volume>20</volume><fpage>56</fpage><lpage>8</lpage></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michael</surname><given-names>J</given-names></name><name><surname>Cobel</surname></name><name><surname>Nicholas</surname><given-names>J</given-names></name></person-group><article-title>Beeching. Brucellosis Harrison's Principle's Internal Medicine</article-title><year>2012</year><volume>1</volume><edition>18th ed</edition><issue>Chapter 157</issue><fpage>1299</fpage><lpage>300</lpage></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colmenero</surname><given-names>JD</given-names></name><name><surname>Reguera</surname><given-names>JM</given-names></name><name><surname>Martos</surname><given-names>F</given-names></name><name><surname>S&#x000e1;nchez-De-Mora</surname><given-names>D</given-names></name><name><surname>Delgado</surname><given-names>M</given-names></name><name><surname>Causse</surname><given-names>M</given-names></name><etal/></person-group><article-title>Complications associated with <italic>Brucella melitensis</italic> infection: A study of 530 cases</article-title><source>Medicine (Baltimore)</source><year>1996</year><volume>75</volume><fpage>195</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">8699960</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solera</surname><given-names>J</given-names></name><name><surname>Geijo</surname><given-names>P</given-names></name><name><surname>Largo</surname><given-names>J</given-names></name><name><surname>Rodriguez-Zapata</surname><given-names>M</given-names></name><name><surname>Gij&#x000f3;n</surname><given-names>J</given-names></name><name><surname>Martinez-Alfaro</surname><given-names>E</given-names></name><etal/></person-group><article-title>A randomized, double-blind study to assess the optimal duration of doxycycline treatment for human brucellosis</article-title><source>Clin Infect Dis</source><year>2004</year><volume>39</volume><fpage>1776</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">15578399</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasanjani</surname><given-names>Roushan MR</given-names></name><name><surname>Mohraz</surname><given-names>M</given-names></name><name><surname>Hajiahmadi</surname><given-names>M</given-names></name><name><surname>Ramzani</surname><given-names>A</given-names></name><name><surname>Valayati</surname><given-names>AA</given-names></name></person-group><article-title>Efficacy of gentamicin plus doxycycline versus streptomycin plus doxycycline in the treatment of brucellosis in humans</article-title><source>Clin Infect Dis</source><year>2006</year><volume>42</volume><fpage>1075</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">16575723</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lulu</surname><given-names>AR</given-names></name><name><surname>Araj</surname><given-names>GF</given-names></name><name><surname>Khateeb</surname><given-names>MI</given-names></name><name><surname>Mustafa</surname><given-names>MY</given-names></name><name><surname>Yusuf</surname><given-names>AR</given-names></name><name><surname>Fenech</surname><given-names>FF</given-names></name></person-group><article-title>Human brucellosis in Kuwait: A prospective study of 400 cases</article-title><source>Q J Med</source><year>1988</year><volume>66</volume><fpage>39</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">3051080</pub-id></element-citation></ref></ref-list></back></article>